Mortality Related to Chronic Obstructive Pulmonary Disease during the COVID-19 Pandemic: An Analysis of Multiple Causes of Death through Different Epidemic Waves in Veneto, Italy.


Journal

International journal of environmental research and public health
ISSN: 1660-4601
Titre abrégé: Int J Environ Res Public Health
Pays: Switzerland
ID NLM: 101238455

Informations de publication

Date de publication:
07 10 2022
Historique:
received: 01 09 2022
revised: 04 10 2022
accepted: 05 10 2022
entrez: 14 10 2022
pubmed: 15 10 2022
medline: 18 10 2022
Statut: epublish

Résumé

Mortality related to chronic obstructive pulmonary disease (COPD) during the COVID-19 pandemic is possibly underestimated by sparse available data. The study aimed to assess the impact of the pandemic on COPD-related mortality by means of time series analyses of causes of death data. We analyzed the death certificates of residents in Veneto (Italy) aged ≥40 years from 2008 to 2020. The age-standardized rates were computed for COPD as the underlying cause of death (UCOD) and as any mention in death certificates (multiple cause of death-MCOD). The annual percent change (APC) in the rates was estimated for the pre-pandemic period. Excess COPD-related mortality in 2020 was estimated by means of Seasonal Autoregressive Integrated Moving Average models. Overall, COPD was mentioned in 7.2% (43,780) of all deaths. From 2008 to 2019, the APC for COPD-related mortality was -4.9% (95% CI -5.5%, -4.2%) in men and -3.1% in women (95% CI -3.8%, -2.5%). In 2020 compared to the 2018-2019 average, the number of deaths from COPD (UCOD) declined by 8%, while COPD-related deaths (MCOD) increased by 14% (95% CI 10-18%), with peaks corresponding to the COVID-19 epidemic waves. Time series analyses confirmed that in 2020, COPD-related mortality increased by 16%. Patients with COPD experienced significant excess mortality during the first year of the pandemic. The decline in COPD mortality as the UCOD is explained by COVID-19 acting as a competing cause, highlighting how an MCOD approach is needed.

Identifiants

pubmed: 36232144
pii: ijerph191912844
doi: 10.3390/ijerph191912844
pmc: PMC9565127
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Références

SSM Popul Health. 2022 Mar;17:101012
pubmed: 34961843
Am J Respir Crit Care Med. 1997 Sep;156(3 Pt 1):814-8
pubmed: 9309998
Eur Respir J. 2006 Oct;28(4):781-5
pubmed: 16807258
Lancet Respir Med. 2014 Jan;2(1):54-62
pubmed: 24461902
Front Med (Lausanne). 2021 Jun 16;8:668808
pubmed: 34222281
COPD. 2018 Apr;15(2):200-205
pubmed: 29697272
Aust N Z J Public Health. 2009 Dec;33(6):551-5
pubmed: 20078573
Euro Surveill. 2020 Nov;25(47):
pubmed: 33243356
Thorax. 2006 Nov;61(11):930-4
pubmed: 16738039
EClinicalMedicine. 2021 Mar;33:100789
pubmed: 33758801
BMJ Open. 2021 Dec 14;11(12):e050525
pubmed: 34907049
BMC Med. 2021 May 17;19(1):124
pubmed: 33993870
Ann Am Thorac Soc. 2021 Jul;18(7):1138-1146
pubmed: 33347376
Eur Respir J. 2003 Nov;22(5):809-14
pubmed: 14621089
Epidemiol Prev. 2019 Mar-Jun;43(2-3):161-170
pubmed: 31293135
Respir Med. 2021 Sep;186:106518
pubmed: 34217049
Sci Rep. 2021 Sep 28;11(1):19251
pubmed: 34584165
J Clin Med. 2021 Mar 07;10(5):
pubmed: 33800097
Lancet Respir Med. 2017 Sep;5(9):691-706
pubmed: 28822787
Arch Bronconeumol. 2022 Apr;58:13-21
pubmed: 35340748
Parkinsonism Relat Disord. 2022 May;98:75-77
pubmed: 35490543
Thromb Res. 2022 Apr;212:44-50
pubmed: 35219931
Euro Surveill. 2012 Apr 05;17(14):
pubmed: 22516003
COPD. 2016;13(1):35-41
pubmed: 26367073
Diabetologia. 2006 Dec;49(12):2878-81
pubmed: 17031611
JAMA. 2021 May 11;325(18):1829-1830
pubmed: 33787821
COPD. 2022;19(1):216-225
pubmed: 35416733
Chin Med J (Engl). 2014;127(9):1619-25
pubmed: 24791864
Thorax. 2019 May;74(5):483-491
pubmed: 30696745
Int J Environ Res Public Health. 2022 Jan 12;19(2):
pubmed: 35055627
PLoS One. 2013 Apr 18;8(4):e61720
pubmed: 23637892
Int J Epidemiol. 2022 Jun 13;51(3):718-726
pubmed: 35288728
Am J Respir Crit Care Med. 2018 Nov 1;198(9):1130-1139
pubmed: 29979608
J Public Health (Oxf). 2004 Mar;26(1):8-12
pubmed: 15044566
MMWR Morb Mortal Wkly Rep. 2022 May 06;71(18):613-618
pubmed: 35511711

Auteurs

Ugo Fedeli (U)

Epidemiological Department, Azienda Zero, Veneto Region, 35131 Padova, Italy.

Claudio Barbiellini Amidei (C)

Epidemiological Department, Azienda Zero, Veneto Region, 35131 Padova, Italy.

Alessandro Marcon (A)

Unit of Epidemiology and Medical Statistics, Department of Diagnostics and Public Health, University of Verona, 37134 Verona, Italy.

Veronica Casotto (V)

Epidemiological Department, Azienda Zero, Veneto Region, 35131 Padova, Italy.

Francesco Grippo (F)

Integrated System for Health, Social Assistance and Welfare, Italian National Institute of Statistics, 00184 Roma, Italy.

Enrico Grande (E)

Integrated System for Health, Social Assistance and Welfare, Italian National Institute of Statistics, 00184 Roma, Italy.

Thomas Gaisl (T)

Department of Pulmonology, University Hospital Zurich, 8091 Zurich, Switzerland.

Stefano Barco (S)

Department of Angiology, University Hospital Zurich, 8091 Zurich, Switzerland.
Center for Thrombosis and Hemostasis, Johannes Gutenberg University Mainz, 55131 Mainz, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH